inbrija-1 Inbrija (levodopa inhalation powder; Acorda Therapeutics) is the first and only FDA-approved inhaled levodopa for intermittent treatment of OFF episodes in patients with Parkinson's disease ...
Backed by phase 3 INHALE-1 data, the expanded indication provides a noninvasive, needle-free mealtime insulin alternative for children and adolescents.
The U.S. Food and Drug Administration has approved Afrezza (insulin human) Inhalation Powder for use in children and ...
All posters will be presented from 4 to 5 p.m. CDT Thursday, June 11, in the exhibition hall. Upon presentation, each publicly presented poster will be available on the publications page of Liquidia’s ...
ProAir Digihaler ProAir® Digihaler® (albuterol sulfate; Teva) Inhalation Powder is now available for patients aged ≥4 years for the treatment or prevention of bronchospasm with reversible obstructive ...
Glucagon-like peptide 1 (GLP 1) analogues enhance insulin secretion, delay gastric emptying, and promote satiety, making them effective therapeutics for type 2 diabetes and obesity [1],[2]. Structural ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
MORRISVILLE, N.C., May 23, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, ...
AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its ...
MannKind recently received U.S. FDA approval for Afrezza Inhalation Powder for children and adolescents aged 6 and older with type 1 or type 2 diabetes, making it the first needle-free mealtime ...
AUSTIN, Texas--(BUSINESS WIRE)--TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its ...